“Bimekizumab versus secukinumab continuous maintenance of response at every visit through one year in patients with moderate to severe plaque psoriasis: Post-hoc results from the BE RADIANT phase 3b trial” (2022) SKIN The Journal of Cutaneous Medicine, 6(6), p. s70. doi:10.25251/skin.6.supp.70.